Please wait while we load the requested 10-K report or click the link below:
|Vice President, Corporate Communications|
|Chief Financial Officer|
ALKERMES REPORTS FINANCIAL RESULTS FOR FISCAL YEAR 2005 AND
PROVIDES FINANCIAL EXPECTATIONS FOR FISCAL YEAR 2006
Reports 78% Increase in Revenues from Risperdal Consta® over Last Fiscal Year
Cambridge, MA, May 19, 2005 Alkermes, Inc. (Nasdaq: ALKS) today reported its financial results for the fiscal year ended March 31, 2005. The net loss on a GAAP basis for the fiscal year was $73.9 million or $0.82 per share as compared to a net loss of $102.4 million or $1.25 per share in the prior year.
The progress Alkermes made during fiscal 2005 has been dramatic. Risperdal Consta® revenues grew strongly, we submitted our New Drug Application for Vivitrex® to the Food and Drug Administration, and we demonstrated significant clinical progress with our diabetes pipeline, stated Richard Pops, chief executive officer of Alkermes. Looking forward to fiscal 2006, we believe that we are in an excellent position to achieve our strategic goals, including meeting our increasing commercial supply requirements for the growing Risperdal Consta business, preparing for the commercial launch of Vivitrex and meeting our product development milestones for the coming year.
Page 1 of 9
The following information was filed by Alkermes Inc on Thursday, May 19, 2005 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Alkermes Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Alkermes Inc.